Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial
Familial dysbetalipoproteinemia (FD) is a genetic disorder associated with impaired postprandial lipid clearance. The effect of adding bezafibrate to standard lipid-lowering therapy on postprandial and fasting lipid levels in patients with FD is unknown. In this randomized placebo-controlled double-...
Main Authors: | Charlotte Koopal, A. David Marais, Jan Westerink, Yolanda van der Graaf, Frank L.J. Visseren |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-11-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520338086 |
Similar Items
-
Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia
by: Klaus G. Parhofer
Published: (2015-10-01) -
Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state
by: Caroline Marcoux, et al.
Published: (2000-09-01) -
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects
by: Rami Batal, et al.
Published: (2000-05-01) -
Cholesterol synthesis in type III hyperlipoproteinemic and non-hyperlipidemic individuals
by: Dendy, Shauneen Marguerite
Published: (2010) -
Lipid-lowering drug prescriptions in a group of Colombian patients
by: Andres Gaviria-Mendoza, et al.
Published: (2019-12-01)